Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma

Avichai Shimoni,S. Zwas,Y. Oksman,Izhar Hardan,Noga Shem-Tov,Avital Rand,Ronit Yerushalmi,Abraham Avigdor,I. Ben-Bassat,Arnon Nagler

Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma

2008

Avichai Shimoni
S. Zwas
Y. Oksman
Izhar Hardan
Noga Shem-Tov
Avital Rand
Ronit Yerushalmi
Abraham Avigdor
I. Ben-Bassat
Arnon Nagler

Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma

Keywords:

Lymphoma
Immunology
Graft-versus-host disease
Non-Hodgkin's lymphoma
Hematology
Radioimmunotherapy
Medicine
Radiation therapy
Transplantation
Ibritumomab tiuxetan
Internal medicine
Transplantation Conditioning
Omega-Conotoxin GVIA
Hematopoietic stem cell transplantation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations